Formulation development of inhalation powders for FK888 with carrier lactose using Spinhaler® and its absorption in healthy volunteers

Journal of Controlled Release

Volumn 97, Issue 1, 2004, Pages 19-29

  Nakate, Toshiomi ^a   Yoshida, Hiromitsu ^a   Ohike, Atsuo ^a   Tokunaga, Yuji ^a   Ibuki, Rinta ^a   Kawashima, Yoshiaki ^b  

^a ASTELLAS PHARMA INC   (Japan)

^b GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Carrier lactose; Dry powder inhaler; Flowability; Pulmonary absorption; Twin impinger

Indexed keywords

ABSORPTION; DEPOSITION; DIGESTIVE SYSTEM; HEALTH; MIXTURES; PATIENT MONITORING; POWDERS;

GASTROINTESTINAL TRACT; INHALATION POWDERS; LACTOSE;

AROMATIC COMPOUNDS;

ALPHA LACTOSE; LACTOSE; N BENZYL N2 [4 HYDROXY 1 [(1 METHYL 1H INDOL 3 YL)CARBONYL]PROLYL] N METHYL 3 (2 NAPHTHYL)ALANINAMIDE; NEUROKININ 1 RECEPTOR ANTAGONIST;

ACTIVE TRANSPORT; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COATED PARTICLE; COLON; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRY POWDER; FLOW RATE; GASTROINTESTINAL TRACT; HUMAN; INHALATION; MALE; NORMAL HUMAN; PH MEASUREMENT; POWDER INHALER; PRIORITY JOURNAL; RESPIRATORY AIRFLOW; SCINTIGRAPHY; SMALL INTESTINE; STOMACH ABSORPTION; TABLET DISINTEGRATION TIME;

ABSORPTION; ADMINISTRATION, INHALATION; ADULT; CHEMISTRY, PHARMACEUTICAL; DIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; HUMANS; INDOLES; LACTOSE; MALE; METERED DOSE INHALERS; POWDERS;

EID: 2442459796     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2004.01.028     Document Type: Article

References (24)

1. Smith P.L. Peptide delivery via the pulmonary route: a valid approach for local and systemic delivery. J. Control. Release. 46:1997;99-106
2. Nicklin P.L., Bayley D., Giddings J., Craig S.J., Cummins L.L., Hastewell J.G., Phillips J.A. Pulmonary bioavailability of a phosphorothioate oligonucleotide (CGP 64128A): comparison with other delivery routes. Pharm. Res. 15:1998;583-591
3. Nakate T., Yoshida H., Ohike A., Tokunaga Y., Ibuki R., Kawashima Y. Improvement of pulmonary absorption of cyclopeptide FK224 in rats by co-formulating with β-cyclodextrin. Eur. J. Pharm. Biopharm. 55:2003;147-154
4. Pedersen S., Frost L., Arnfred T. Errors in inhalation technique and efficiency in inhaler use in asthmatic children. Allergy. 41:1986;118-124
5. Guidry G.G., Brown W.D., Stogner S.W., George R.B. Incorrect use of metered dose inhalers by medical personnel. Chest. 101:1992;31-33
6. Mcfadden E.R. Improper patient techniques with metered dose inhalers: clinical consequences and solutions to misuse. J. Allergy Clin. Immunol. 96:1995;278-283
7. Borgström L., Bengtsson T., Derom E., Pauwels R. Variability in lung deposition of inhaled drug, within and between asthmatic patients, with a pMDI and a dry powder inhaler, Turbohaler® Int. J. Pharm. 193:2000;227-230
8. Hartley J., Nogrady S., Gibby O. Bronchodilator effects of dry salbutamol powder administrated by rotahaler. Br. J. Clin. Pharm. Suppl. 4:1977;673-675
9. Prime D., Atkins P.J., Slater A., Sumby B. Review of dry powder inhalers. Adv. Drug Deliv. Rev. 26:1997;51-58
10. Selroos O., Pietinalho A., Riska H. Delivery devices for inhaled asthma medication. Clin. Immunother. 6:1996;273-299
11. Timsina M.P., Martin G.P., Marriott C., Ganderton D., Yianneskis M. Drug delivery to the respiratory tract using dry powder inhalers. Int. J. Pharm. 101:1994;1-13
12. Higham M.A., Sharara A.M., Magee R.P., Ind P.W. Determination of the minimum dose of lactose drug carrier that can be sensed during inhalation. Br. J. Clin. Pharmacol. 40:1995;281-282
13. Bell J.H., Hartley P.S., Cox J.S.G. Dry powder aerosols: 1. A new powder inhalation device. J. Pharm. Sci. 60:1971;1559-1564
14. Bosquillon C., Lombry C., Préat V., Vanbever R. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J. Control. Release. 70:2001;329-339
15. Kassem N.M., Ganderton D. The influence of carrier surface on the characteristics of inspirable powder aerosols. J. Pharm. Pharmacol. 42:1990;11P
16. Kawashima Y., Serigano T., Hino T., Yamamoto H., Takeuchi H. Effect of surface morphology of carrier lactose on dry powder inhalation property of pranlukast hydrate. Int. J. Pharm. 172:1998;178-188
17. Kassem N.M., Ho K.K.L., Ganderton D. The effect of air flow and carrier size on the characteristics of an inspirable cloud. J. Pharm. Pharmacol. 41:1989;14P
18. Steckle H., Müller B.W. In vitro evaluation of dry powder inhalers: II. Influence of carrier particle size and concentration on in vitro deposition. Int. J. Pharm. 154:1997;31-37
19. Hallworth G.W., Westmoreland D.G. The twin impinger: a simple device for assessing the delivery of drugs from metered dose pressurized aerosol inhalers. J. Pharm. Pharmacol. 39:1987;966-972
20. Hino T., Serigano T., Yamamoto H., Takeuchi H., Niwa T., Kawashima Y. Particle design of Wogon extract dry powder for inhalation aerosols with granulation method. Int. J. Pharm. 168:1998;59-68
21. Zeng X.M., Pandhal K.H., Martin G.P. The influence of lactose carrier on the content homogeneity and dispersibility of beclomethasone dipropionate from dry powder aerosols. Int. J. Pharm. 197:2000;41-52
22. Steckel H., Müler B.W. In vitro evaluation of dry powder inhalers: I. Drug deposition of commonly used devices. Int. J. Pharm. 154:1997;19-29
23. Karhu M., Kuikka J., Kauppinen T., Bergström K., Vidgren M. Pulmonary deposition of lactose carriers used in inhalation powders. Int. J. Pharm. 196:2000;95-103
24. Baldrick P., Bamford D.G. A toxicological review of lactose to support clinical administration by inhalation. Food Chem. Toxicol. 35:1997;719-733